Effects of CYP3A5 polymorphism and the tacrolimus 12 h concentration on tacrolimus-induced acute renal dysfunction in patients with lupus nephritis

References

• Chen W, Liu Q, Chen W, et al. (2012). Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 21:944–52
   PubMed Web of Science ®Google Scholar
• Chen W, Tang X, Liu Q, et al. (2011). Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis 57:235–44
   PubMed Web of Science ®Google Scholar
• De BK, Jimenez E, De S, et al. (2009). Analytical performance characteristics of the Abbott Architect i2000 Tacrolimus assay; comparisons with liquid chromatography-tandem mass spectrometry (LC–MS/MS) and Abbott IMx methods. Clin Chim Acta 410:25–30
   PubMed Web of Science ®Google Scholar
• Font J, Ramos-Casals M, Cervera R, et al. (2001). Cardiovascular risk factors and the long-term outcome of lupus nephritis. QJM 94:19–26
   PubMed Web of Science ®Google Scholar
• Fukuen S, Fukuda T, Maune H, et al. (2002). Novel detection assay by PCR–RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12:331–4
   PubMedGoogle Scholar
• Haehner BD, Gorski JC, Vandenbranden M, et al. (1996). Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 50:52–9
   PubMed Web of Science ®Google Scholar
• Hesselink DA, Bouamar R, Elens L, et al. (2014). The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet 53:123–39
   PubMed Web of Science ®Google Scholar
• Hirai F, Takatsu N, Yano Y, et al. (2014). Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. J Gastroenterol Hepatol 29:60–6
   PubMed Web of Science ®Google Scholar
• Hiratsuka M, Takekuma Y, Endo N, et al. (2002). Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 58:417–21
   PubMed Web of Science ®Google Scholar
• Kershner RP, Fitzsimmons WE. (1996). Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 62:920–6
   PubMed Web of Science ®Google Scholar
• Kino T, Hatanaka H, Hashimoto M, et al. (1987). FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 40:1249–55
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–91
   PubMed Web of Science ®Google Scholar
• Laskow DA, Vincenti F, Neylan JF, et al. (1996). An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 62:900–5
   PubMed Web of Science ®Google Scholar
• Lee YH, Lee HS, Choi SJ, et al. (2011). Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus 20:636–40
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang H, Liu Z, et al. (2015). Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 162:18–26
   PubMed Web of Science ®Google Scholar
• Miura M, Niioka T, Kagaya H, et al. (2011a). Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. J Clin Pharm Ther 36:208–16
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Kagaya H, et al. (2011b). Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics 12:977–84
   PubMed Web of Science ®Google Scholar
• Sakuma S, Kato Y, Nishigaki F, et al. (2001). Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. Int Immunopharmacol 1:749–57
   PubMed Web of Science ®Google Scholar
• Sakuma S, Kato Y, Nishigaki F, et al. (2000). FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol 130:1655–63
   PubMed Web of Science ®Google Scholar
• Scott LJ, McKeage K, Keam SJ, Plosker GL. (2003). Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 63:1247–97
   PubMed Web of Science ®Google Scholar
• Siekierka JJ, Sigal NH. (1992). FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond. Curr Opin Immunol 4:548–52
   PubMed Web of Science ®Google Scholar
• Staatz CE, Goodman LK, Tett SE. (2010a). Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet 49:207–21
   PubMed Web of Science ®Google Scholar
• Staatz CE, Goodman LK, Tett SE. (2010b). Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 49:141–75
   PubMed Web of Science ®Google Scholar
• Staatz CE, Tett SE. (2004). Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43:623–53
   PubMed Web of Science ®Google Scholar
• Szeto CC, Kwan BC, Lai FM, et al. (2008). Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) 47:1678–81
   PubMed Web of Science ®Google Scholar
• Takahashi S, Hiromura K, Sakurai N, et al. (2011). Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis. Mod Rheumatol 21:282–9
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Kawai S, Yamamoto K, et al. (2014). Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3267 Japanese patients with rheumatoid arthritis. Mod Rheumatol 24:8–16
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, et al. (1982). The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–7
   PubMed Web of Science ®Google Scholar
• Tanaka K, Terao C, Ohmura K, et al. (2014). Significant association between CYP3A5 polymorphism and blood concentration of tacrolimus in patients with connective tissue diseases. J Hum Genet 59:107–9
   PubMed Web of Science ®Google Scholar
• Uchida K, Asamiya Y, Takei T, et al. (2010). Pharmacokinetics of orally administered tacrolimus in lupus nephritis patients. Yakugaku Zasshi 130:113–18
   PubMed Web of Science ®Google Scholar
• Uchino A, Tsukamoto H, Nakashima H, et al. (2010). Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol 28:6–12
   PubMed Web of Science ®Google Scholar
• Vincenti F, Laskow DA, Neylan JF, et al. (1996). One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the US Multicenter FK506 Kidney Transplant Group. Transplantation 61:1576–81
   PubMed Web of Science ®Google Scholar
• Waldman M, Appel GB. (2006). Update on the treatment of lupus nephritis. Kidney Int 70:1403–12
   PubMed Web of Science ®Google Scholar